average improvement in the overall quality of life score was seen by 2 points.
INTRODUCTION:
Secondary lymphedema is a chronic and debilitating complication of breast cancer therapy affecting more than one in five breast cancer survivors. 1 In this patient population, patient-reported outcomes may be more important in predicting long-term health-related quality of life (HRQoL) than clinician measured outcomes.
2 Cost-effectiveness analysis can be used to compare different treatment modalities based on HRQoL. 3 The aim of this study was to (1) assess reported HRQoL measures following vascularized lymph node transfer (VLNT) and complex decongestive therapy (CDT) and (2) determine the suitability of current data to design a costeffectiveness analysis able to inform lymphedema treatment decisions.
METHODS:
A literature review was performed to identify studies measuring HRQoL in patients with breast cancer-related lymphedema (BCRL) following either CDT or VLNT. Eleven studies were included, three for VLNT and eight for CDT, all of which used lymphedema-specific measurements. VLNT patients were evaluated with LYMQOL or ULL-27. CDT patients were evaluated with SF-36, FACT-B, EORTC QLQ-C30, EORTC QLQ-BR23, or WCLS. We assessed the ability of current data on HRQoL to meet the requirements of a cost-effectiveness analysis, specifically the availability of generic preference-weights for outcomes of interest.
RESULTS:
Significant improvements in HRQoL were reported in all studies for VLNT and all, except for two, studies for CDT. However, HRQoL was reported using a variety of lymphedemaspecific instruments which limited the ability for comparison. Cost-effectiveness analysis requires a common metric to compare the value of alternative treatment options. This method is limited by the use of a preference-weights to measure HRQoL, which is less sensitive to the impact of lymphedema-specific complications.
CONCLUSION:
In deciding among BCRL treatment modalities, cost-effectiveness analysis is a valuable method providing information on the incremental benefit of each alternative. Current data is not sufficient to compare HRQoL among treatment options nor to conduct an adequate cost-effectiveness analysis. Further study is required to determine HRQoL using preferencebased utility measures.
